Catalog No.: PC-38680Not For Human Use, Lab Use Only.
Firzacorvir (ABI-H2158) is a novel potent HBV core inhibitor structurally distinct from other core inhibitors, ABI-H2158 is a pan-genotypic HBV inhibitor with EC50s ranging from 7.1 to 22 nM across HBV genotypes A-E.
Firzacorvir (ABI-H2158) is a novel potent HBV core inhibitor structurally distinct from other core inhibitors, ABI-H2158 is a pan-genotypic HBV inhibitor with EC50s ranging from 7.1 to 22 nM across HBV genotypes A-E.
ABI-H2158 inhibited HBV replication by blocking pgRNA encapsidation in induced HepAD38 cells (EC50=22 nM) and had similar potency in HBV-infected HepG2-NTCP cells (EC50=27 nM) and primary human hepatocytes (PHH) (EC50=41 nM).
ABI-H2158 also potently blocked the formation of cccDNA in de novo HBV infections with EC50s of 200 nM in HepG2-NTCP and PHH assays.
ABI-H2158 has dual mechanisms of action, inhibiting both early and late steps of the HBV replication cycle.
